AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03755232 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: water or dextrose or white bread
Study NCT02984059 — intervention group
Intervention type: GENETIC
Intervention: Genomic DNA
Description: blood draw
Study NCT02984059 — intervention group
Intervention type: GENETIC
Intervention: RNA analysis
Description: Mucosal Biopsy via colonoscopy
Study NCT02984059 — intervention group
Intervention type: GENETIC
Intervention: Microbiome
Description: Stool microbiome
Study NCT02984059 — intervention group
Intervention type: OTHER
Intervention: Calprotectin
Description: stool or blood analysis for calprotectin
Study NCT02984059 — intervention group
Intervention type: OTHER
Intervention: Pain questionnaires
Description: PSDS PCS-C/P PBI APPT
Study NCT02984059 — intervention group
Intervention type: OTHER
Intervention: Anxiety/Depression Questionnaires
Description: RCADS-25 CSI-24 ARCS
Study NCT04754685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intra-articular injection of platelet-rich plasma
Description: The patient was put in 20 degree flexion in supine position with the knee. Under aseptic conditions, a 21-gage needle was used to inject 5 mL of PRP into the suprapatellar knee joint pouch, using a superolateral method. Local anesthetics were not used. Patients were instructed after the injection to refrain from physical exercise for at least 24 hours but no restriction was specified regarding activities of daily living. Three IA-PRP injections were administered at 2-week intervals. The same physician who was engaged in selecting and testing participants did the injections
Study NCT03876600 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Replacement of permanent pacemakers for elective wear.
Description: START's intervention is a replacement of permanent pacemakers for elective wear, for the both arms the surgical intervention is the same. The surgical procedure is the same in the both arms.~The differences are in conventional hospitalization, patient comes to hospital one day before operation and he can go out one day after operation. In ambulatory patient come to hospital operation days and he can got out the same day.
Study NCT03876600 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Replacement of permanent pacemakers for elective wear.
Description: START's intervention is a replacement of permanent pacemakers for elective wear, for the both arms the surgical intervention is the same. The surgical procedure is the same in the both arms.~The differences are in conventional hospitalization, patient comes to hospital one day before operation and he can go out one day after operation. In ambulatory patient come to hospital operation days and he can got out the same day.
Study NCT03242252 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet (identical to sotagliflozin 200 mg in appearance), orally once daily.~Route of administration: Oral
Study NCT03242252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet (identical to sotagliflozin 200 mg in appearance), orally once daily.~Route of administration: Oral
Study NCT03242252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Description: Sotagliflozin 200 mg, tablet, orally once daily.~Route of administration: Oral
Study NCT04286672 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Metadherin
Description: study alterations of MTDH gene expression in the serum of bladder cancer patients
Study NCT03135925 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Supervised Exercise Program
Description: Participants will be invited to attend a weekly supervised exercise program over six weeks, in the time before their bone marrow transplantation
Study NCT04603222 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SUMMIT BRUSH
Description: SUMMIT BRUSH used for the treatment of blepharitis
Study NCT04603222 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ocusoft Lid Scrub Original Foaming Eyelid Cleanser
Description: treating blepharitis with Ocusoft Lid Scrub Original Foaming Eyelid Cleanser
Study NCT04603222 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ocusoft Lid Scrub Original Foaming Eyelid Cleanser
Description: treating blepharitis with Ocusoft Lid Scrub Original Foaming Eyelid Cleanser
Study NCT03678831 — intervention group
Intervention type: PROCEDURE
Intervention: tissue
Description: Adipocyte isolation from distal femoral epiphysis and subcutaneous adipose tissue at the surgery site; classical piece removal during prosthetic replacement of the knee
Study NCT05052437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utidelone Injection; capecitabine
Description: 8 patients will be assigned to utidelone plus capecitabine arm receiving utidelone plus capecitabine. Utidelone injection 30mg/m2/day, intravenously administered once a day for 5 consecutive days; capecitabine tablets, 1000mg/m2, orally, 2 times a day for 14 consecutive days. 21 days is a cycle
Study NCT05052437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utidelone
Description: 8 patients will be assigned to utidelone arm and receive utidelone injection 30 mg/m2/day intravenously, once a day for 5 consecutive days in a 21-day cycle.
Study NCT01287195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral OKT3
Description: 1 mg or 2 mg Oral OKT3 will be given orally to participants once daily for 30 days
Study NCT01287195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: 20 mg Omeprazole will be given orally to participants once daily for 30 days
Study NCT01319721 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MMC
Description: Intraoperative 0.2mg/ml mitomycin C (0.02%) for 3 minutes will be applied topically after extensive excision of recurrent pterygium.
Study NCT01319721 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LCAG
Description: Limbal conjunctival autograft transplantation will be applied to closure of conjunctival defect after extensive excision of recurrent pterygium.
Study NCT01319721 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AMG
Description: Amniotic membrane graft transplantation will be applied to closure of conjunctival defect after extensive excision of recurrent pterygium.
Study NCT00004984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Insulin
Description: Capsules oral insulin, 7.5 mg of recombinant human insulin crystals
Study NCT00004984 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for oral insulin
Study NCT03247075 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy
Description: Guided Internet-delivered CBT includes exposure training, coping techniques and cognitive components, intended to reduce social anxiety symptoms
Study NCT03247075 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Support and Counseling
Description: Guided Internet-delivered support and counseling includes educative material about social anxiety and health related issues such as physical activity, nutritious diet, sleep habits etc.
Study NCT03099044 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Subjects consume 2 placebo beverages daily for 10 days. The dose-response controls for volume consumed.
Study NCT03099044 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single Active dose
Description: Subjects consume 1 placebo + 1 Active beverages daily for 10 days. The dose-response controls for volume consumed.
Study NCT03099044 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Double Active dose
Description: Subjects consume 2 Active beverages daily for 10 days. The dose-response controls for volume consumed.
Study NCT02123355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction of anesthesia
Description: Midazolam 0.05 mg/kg、Propofol 1.0 mg/kg、Sufentanyl 3μg/kg、Victracurium 0.1 mg/kg sequential intravenous injection
Study NCT02123355 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Induction of anesthesia
Description: Midazolam 0.05 mg/kg、Propofol 1.0 mg/kg、Sufentanyl 3μg/kg、Victracurium 0.1 mg/kg sequential intravenous injection
Study NCT02123355 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intubation
Description: After muscle relaxed and loss of eyelash reflex of the patients, intubation is done,then mechanical ventilation is performed, and maintain the PETCO2于35\~40 mmHg，pulse oxygen saturation is more than 95%.
Study NCT02123355 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Intubation
Description: After muscle relaxed and loss of eyelash reflex of the patients, intubation is done,then mechanical ventilation is performed, and maintain the PETCO2于35\~40 mmHg，pulse oxygen saturation is more than 95%.
Study NCT02123355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane, remifentanil ,vecuronium
Description: Sevoflurane（1%-2%）is inspirated, and remifentanil 0.1-0.5μg/kg//min is continuously pumped,vecuronium 0.03 mg/kg is injected intermittently.
Study NCT02123355 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sevoflurane, remifentanil ,vecuronium
Description: Sevoflurane（1%-2%）is inspirated, and remifentanil 0.1-0.5μg/kg//min is continuously pumped,vecuronium 0.03 mg/kg is injected intermittently.
Study NCT05551624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 Mg Oral Tablet + N-acetylcysteine 400 mg Oral tablet
Description: Oral tablets administered daily, atorvastatin once a day and N-acetylcysteine every 8 hours
Study NCT02123355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine is given at 0.5μg/kg/h by continuous infusion and is stopped to given 30 minutes before the surgery is over.
Study NCT02123355 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Normal saline is given at 0.5μg/kg/h by continuous infusion and is stopped to given 30 minutes before the surgery is over.
Study NCT04250571 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: information about No treatment group
Description: Participants will receive no pills and will be told that they are in the no treatment group
Study NCT04250571 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: imaginary pill technique
Description: Participants will be instructed to take an imagined pill. This instruction consists of a procedure including five steps (i.e., identifying the IP sensitive problem, building trust/belief/reality of the IP, constructing a personally meaningful IP, taking the IP, suggestions for self-administering the IP in real life, and building adherence). Participants in this group receive daily e-mail reminders.
Study NCT04250571 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: open label placebo
Description: Participants will have the information that they are receiving inert pills (i.e. P-Dragees, containing Placebo), combined with the following scientific rationale: (a) deceptive as well as open label placebos have been found to be effective in relieving symptoms in a variety of clinical conditions namely anxiety, depression, chronic pain (the placebo effect is powerful), (b) classical conditioning are one of the possible mechanism of this effect (the body automatically responds), (c) positive expectations may help but are not necessary, (suspend disbelief), (d) compliance with these instructions are important for outcome (taking the pills faithfully is important).~Participants in this group receive daily e-mail reminders.
Study NCT03542435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SXC-2023
Description: Oral capsule
Study NCT03542435 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00840580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 0.5% ophthalmic solution (Vigamox)
Description: One drop 4 times a day in study eye for one week prior to surgery, followed by one drop 4 times a day for two weeks beginning Day 1 post surgery.
Study NCT00840580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin 0.5% ophthalmic solution (Cravit)
Description: One drop 4 times a day in study eye for one week prior to surgery, followed by one drop 4 times a day for two weeks beginning Day 1 post surgery.
Study NCT01968057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally
Study NCT01968057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclosporin
Description: Administered orally
Study NCT01116427 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: abatacept
Description: In core/extension phase: administered IV at weeks 0/28, 2/30, and 4/32, and then every 4 weeks until week 24/52; Dosing: less than 60 kg, 500 mg; 60-100 kg, 750 mg; or greater than 100 kg, 1 gram
Study NCT01116427 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: abatacept
Description: In core/extension phase: administered IV at weeks 0/28, 2/30, and 4/32, and then every 4 weeks until week 24/52; Dosing: less than 60 kg, 500 mg; 60-100 kg, 750 mg; or greater than 100 kg, 1 gram
Study NCT01116427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: In core/extension phase: administered IV at weeks 0/28, 2/30, and 4/32, and then every 4 weeks until week 24/52
Study NCT01116427 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In core/extension phase: administered IV at weeks 0/28, 2/30, and 4/32, and then every 4 weeks until week 24/52
Study NCT00478790 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ologen™ Collagen matrix implantation in glaucoma filtering surgery
Description: ologen™ treatment is used, the collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy.
Study NCT03422692 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BioXclude amnion-chorion membrane
Description: BioXclude will be used for the prevention of alveolar ridge resorption via socket bone graft and amnion-chorion membrane closure
Study NCT03422692 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mem-Lok collagenous membrane
Description: Mem-Lok will be used for the prevention of alveolar ridge resorption via socket bone graft and collagenous membrane closure
Study NCT03913195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibalizumab-uiyk
Description: Ibalizumab-uiyk is an IgG4 monoclonal antibody targeting domain 2 of the extracellular portion of the CD4 protein. Ibalizumab-uiyk is FDA approved for the treatment of multi-drug resistant HIV in treatment experienced patients.
Study NCT02893124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa
Description: peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week, for at most 96 weeks.
Study NCT02447094 — intervention group
Intervention type: DRUG
Intervention: Alteplase
Description: Intravenous (i.v.) tPA per the standard of care
Study NCT02514005 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual therapy
Description: - Manual Therapy. Study treatment consists of a comprehensive joint treatment of the lumbar region and the lower limbs that are related to the biomechanics of the knee. In this way, the aim is to globally balance the possible dysfunctions that may exist in the lower lumbar region and sacroiliac joint, hip, knee and ankle.
Study NCT02514005 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: - Manual Therapy. Study treatment consists of a comprehensive joint treatment of the lumbar region and the lower limbs that are related to the biomechanics of the knee. In this way, the aim is to globally balance the possible dysfunctions that may exist in the lower lumbar region and sacroiliac joint, hip, knee and ankle.
Study NCT02514005 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: * Manual therapy. Study treatment consists of a comprehensive joint treatment of the lumbar region and the lower limbs that are related to the biomechanics of the knee. In this way, the aim is to globally balance the possible dysfunctions that may exist in the lower lumbar region and sacroiliac joint, hip, knee and ankle.~* Dry needling (DN). Dry needling is performed in the MTrPs of the vastus lateralis and vastus medialis muscles of the quadriceps.
Study NCT00461305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRSP 3 mg/EE 20 µg (13 cycles)
Description: 1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 µg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle; treatment duration 52 weeks (13 cycles)
Study NCT00461305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRSP 3 mg/EE 30 µg (6 cycles)
Description: 1 tablet per day Drospirenone 3 mg/Ethinylestradiol 30 µg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle; treatment duration 24 weeks (6 cycles)
Study NCT02099305 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adolescent Depression Awareness Program (ADAP)
Description: Depression education curriculum delivered by trained school health education teachers or other school personnel
Study NCT02479776 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: stem cell injection
Description: Injection of autologous bone marrow derived stem cells
Study NCT03131596 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IUB dilatation therapy
Description: A Foley catheter (size 14fr) will be prepared by cutting the excess catheter tip protruding beyond the balloon prior to insertion into the uterine cavity. Once the catheter has reached the fundus, 3-4.5mls of saline will be slowly introduced into the balloon under ultrasound guidance, in order to directly visualize the distention of the cavity and division of any intrauterine adhesions, if present.
Study NCT04182061 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The AMTE protocol
Description: The AMTE program is an adaptation of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Adolescents (UP-A; Ehrenreich-May et al., 2018) to be applied as an internet-based protocol. Like the UP-A, the program AMTE implements a set of core principles to address common factors underling youth anxiety and depressive symptoms. It includes the following 10 modules: (1) Understanding emotional problems and disorders, (2) Getting to know your emotions and behaviors, (3) Enjoy your positive activities, (4) Mindful emotion awareness, (5) Being flexible in your thinking, (6) Confronting physical sensations, (7) Situational emotion exposure, (8) How to regulate the emotional avoidance, (9) Respiratory relaxation training, and (10) Relapse prevention.
Study NCT02436070 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted text messages
Description: Subjects received text messages specific to post ED asthma follow-up
Study NCT02436070 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General text messages
Description: Subjects received text messages generalized to children with asthma
Study NCT04367467 — intervention group
Intervention type: OTHER
Intervention: Kidney Function Test
Description: Cystatin-C measurement
Study NCT03590054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abexinostat
Description: Given orally (PO) twice a day (BID) days 1-4, 8-11 of every 21 day cycle
Study NCT02064972 — intervention group
Intervention type: OTHER
Intervention: Patients undergoing allo-HSCT, who manifest GvHD.
Description: Changes in CEC counts in relation to GvHD ONSET
Study NCT00162266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept (BMS-188667)
Description: IV, 10 mg/Kg, monthly, for the duration of the trial
Study NCT00162266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept (BMS-188667)
Description: Intravenous (IV) infusion, 2 mg/kg, infused intravenously for approximately 30 min, infusions on Days 1, 15, 30 and monthly thereafter for 12 months
Study NCT00162266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept (BMS-188667)
Description: Intravenous (IV) infusion, 10 mg/kg, infused intravenously for approximately 30 min, infusions on Days 1, 15, 30 and monthly thereafter for 12 months
Study NCT00162266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous (IV) infusion, 0 mg/kg, infused intravenously for approximately 30 min, infusions on Days 1, 15, 30 and monthly thereafter for 12 months
Study NCT03785951 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein Isolate
Description: Whey protein product isolated from whole milk. 79% Protein with minimal carbohydrate and fat.~50 grams of total supplemental protein/amino acids from whey protein powder consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks in the form of a nutritional shake.
Study NCT03785951 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wheat Protein
Description: Enzymatically hydrolysed wheat protein containing wheat peptides. 75% Protein with minimal carbohydrate and fat.~50 grams of total supplemental protein/amino acids from whet protein peptide powder consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks in the form of a nutritional shake.
Study NCT04672447 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Citrulline
Description: Four weeks of oral L-Citrulline (2 grams/day) supplementation. Supplementation will be ingested daily, half of the doses in the morning and half at night.
Study NCT04672447 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Citrulline
Description: Four weeks of oral L-Citrulline (6 grams/day) supplementation. Supplementation will be ingested daily, half of the doses in the morning and half at night.